According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Jubilant Cadista will submit an appropriate action plan to the USFDA on these observations
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
New research labs and process development services to enable next generation therapeutics
Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Campaign launched to spread awareness regarding dengue prevention and control
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
Subscribe To Our Newsletter & Stay Updated
